CELL INTELLIGENCE · 肿瘤细胞治疗研究

Claudin-18.2：从分子机制到实体瘤临床转化（综述）

Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

基于纳米抗体的 CLDN18.2 CAR-T IMC002 的临床前开发及一例病例报告：靶向非肿瘤毒性降低

Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity.

2025 年晚期胰腺癌的系统治疗：当前标准治疗与新兴治疗策略

Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies.

胰腺癌新兴嵌合抗原受体免疫细胞治疗：机制、临床进展与未来展望

Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives.

FNDC4 驱动胰腺癌的转移和免疫逃逸

FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer.

靶向 Claudin 18.2 的 VHH 基 CAR-T 细胞在胰腺癌模型中显示高疗效

VHH-based CAR-T cells targeting Claudin 18.2 show high efficacy in pancreatic cancer models.

本研究建立了一套开发 CLDN18.2 特异性 VHH 的有效框架，并证明其可成功整合到 CAR-T 细胞治疗中。

局部放疗极化的肿瘤相关巨噬细胞增强 Claudin18.2 靶向 CAR-T 治疗胰腺癌的疗效

Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer.

局部放疗显著增强了靶向 CLDN18.2 的 CAR-T 疗法对胰腺导管腺癌（PDAC）的抗肿瘤疗效。

IDO1 抑制通过克服肿瘤微环境中犬尿氨酸介导的代谢抑制增强胃肠道肿瘤 CLDN18.2-CAR-T 细胞治疗

IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor

靶向 IDO1 是克服胃肠道癌症免疫抑制屏障、提高 CLDN18.2-CAR-T 疗法疗效的一种有前景的策略。这些发现凸显了将 IDO1 抑制整合到 CAR-T 治疗方案中以解决难治性癌症耐药问题的潜力。

采用抗体依赖性安全策略的 claudin18.2 靶向 CAR-T 细胞治疗晚期胰腺癌的高疗效

The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy.